Stockreport

Catabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and Substantially Slowed Duchenne Muscular Dystrophy Disease Progression Through More Than One Year of Treatment

Catabasis Pharmaceuticals, Inc.  (CATB) 
Last catabasis pharmaceuticals, inc. earnings: 3/10 08:05 am Check Earnings Report
US:NASDAQ Investor Relations: ir.catabasis.com/investor-overview
PDF -- Consistent Improvements Sustained Across All Assessments of Muscle Function Through 48 and 60 Weeks of Edasalonexent Treatment in MoveDMD® Trial -- [Read more]